171 related articles for article (PubMed ID: 37584725)
21. Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.
Popp I; Del Pozzo L; Waser B; Reubi JC; Meyer PT; Maecke HR; Gourni E
Nucl Med Biol; 2017 Feb; 45():22-29. PubMed ID: 27865999
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
23. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
24. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
25. Development and biodistribution studies of
Ma L; Grant C; Gallazzi F; Watkinson LD; Carmack TL; Embree MF; Smith CJ; Medvedev D; Cutler CS; Li Y; Wilbur DS; Hennkens HM; Jurisson SS
Nucl Med Biol; 2022; 108-109():61-69. PubMed ID: 35325810
[TBL] [Abstract][Full Text] [Related]
26. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
[TBL] [Abstract][Full Text] [Related]
27. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
[TBL] [Abstract][Full Text] [Related]
28. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee Sy; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Feb; 42(2):131-6. PubMed ID: 25457455
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with
Holzleitner N; Cwojdzinski T; Beck R; Urtz-Urban N; Hillhouse CC; Grundler PV; van der Meulen NP; Talip Z; Ramaekers S; Van de Voorde M; Ponsard B; Casini A; Günther T
J Nucl Med; 2024 Mar; 65(3):481-484. PubMed ID: 38124121
[TBL] [Abstract][Full Text] [Related]
31. Single vial cold kits optimized for preparation of gastrin releasing peptide receptor (GRPR)-radioantagonist
Vats K; Sharma R; Kameswaran M; Satpati D; Dash A
J Pharm Biomed Anal; 2019 Jan; 163():39-44. PubMed ID: 30278325
[No Abstract] [Full Text] [Related]
32. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
[TBL] [Abstract][Full Text] [Related]
33. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.
Mansi R; Wang X; Forrer F; Waser B; Cescato R; Graham K; Borkowski S; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):97-107. PubMed ID: 20717822
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Comparison of the
Koller L; Joksch M; Schwarzenböck S; Kurth J; Heuschkel M; Holzleitner N; Beck R; von Amsberg G; Wester HJ; Krause BJ; Günther T
J Nucl Med; 2023 Oct; 64(10):1654-1659. PubMed ID: 37934025
[TBL] [Abstract][Full Text] [Related]
35. Matched-pair,
Bandara N; Stott Reynolds TJ; Schehr R; Bandari RP; Diebolder PJ; Krieger S; Xu J; Miao Y; Rogers BE; Smith CJ
Nucl Med Biol; 2018; 62-63():71-77. PubMed ID: 29929115
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
[TBL] [Abstract][Full Text] [Related]
37. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent
Schreck MV; Burgard C; Schmidtke A; Hierlmeier I; Stemler T; Maus S; Rosar F; Jung M; Speicher A; Ezziddin S; Holland JP; Bartholomä MD
Mol Pharm; 2023 Dec; 20(12):6463-6473. PubMed ID: 37978936
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
[TBL] [Abstract][Full Text] [Related]
39. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.
Jamous M; Tamma ML; Gourni E; Waser B; Reubi JC; Maecke HR; Mansi R
Nucl Med Biol; 2014 Jul; 41(6):464-70. PubMed ID: 24780298
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
